Camp4 Therapeutics (CAMP) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CAMP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Camp4 Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$7.75 |
| 52 Week Low | US$1.41 |
| Beta | 0 |
| 1 Month Change | 41.77% |
| 3 Month Change | -0.67% |
| 1 Year Change | 189.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.21% |
Recent News & Updates
Camp4 Moves Into Human Trials -- The Upside Is Underpriced
Summary Camp4 Therapeutics remains a buy as CMP-002 transitions to first-in-human Phase 1/2 trials, shifting the story to a catalyst-driven setup. The pro forma cash position, bolstered by a $50M tranche, extends the runway into 2029, supporting execution through key clinical readouts. Valuation appears optically expensive on traditional multiples, but enterprise value remains modest, reflecting both execution risk and upside potential if clinical data validates the platform. Key risk centers on CMP-002's first-in-human translation; failure would likely drive a sharp valuation reset and force strategic pivots. Read the full article on Seeking AlphaWe Think Camp4 Therapeutics (NASDAQ:CAMP) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Camp4 Therapeutics...Recent updates
Shareholder Returns
| CAMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.6% | 7.1% | -1.5% |
| 1Y | 189.0% | 45.3% | 17.8% |
Return vs Industry: CAMP exceeded the US Biotechs industry which returned 45.3% over the past year.
Return vs Market: CAMP exceeded the US Market which returned 17.8% over the past year.
Price Volatility
| CAMP volatility | |
|---|---|
| CAMP Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CAMP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CAMP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 48 | Josh Mandel-Brehm | www.camp4tx.com |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders.
Camp4 Therapeutics Corporation Fundamentals Summary
| CAMP fundamental statistics | |
|---|---|
| Market cap | US$281.13m |
| Earnings (TTM) | -US$107.24m |
| Revenue (TTM) | US$4.22m |
Is CAMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAMP income statement (TTM) | |
|---|---|
| Revenue | US$4.22m |
| Cost of Revenue | US$38.69m |
| Gross Profit | -US$34.47m |
| Other Expenses | US$72.77m |
| Earnings | -US$107.24m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | -817.69% |
| Net Profit Margin | -2,543.74% |
| Debt/Equity Ratio | 0% |
How did CAMP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 10:39 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Camp4 Therapeutics Corporation is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |
| Anupam Rama | J.P. Morgan |